Inflammatory Autoimmune Articles & Analysis: Older
21 news found
Therefore, flow cytometry is widely used in clinical diagnosis and medical research, such as tumor-associated diseases, autoimmune diseases, cardiovascular diseases, inflammatory infections and infectious diseases, providing higher clinical value for differential diagnosis, treatment monitoring and condition assessment. ...
Furthermore, Creative Diagnostics' services cover a variety of diseases, including cardiovascular diseases, oncology, inflammatory and autoimmune diseases, infectious diseases, and psychiatric disorders. ...
Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. ...
The analysis was carried out by researchers at Lund University and provides additional support for the application of the therapeutic diabetes vaccine Diamyd® to prevent or delay clinical type 1 diabetes, and aligns with the rationale of the VINNOVA-financed ASSET project (AI for Sustainable Prevention of Autoimmunity in the Society) coordinated by Diamyd Medical. ...
“These results highlight the potential of PAD4 inhibition as a novel treatment approach for cancer in addition to the previously established role of this pathway in autoimmune diseases," said Luca Rastelli, Ph.D., Chief Scientific Officer, Jubilant Therapeutics Inc. "We are developing several highly selective oral, small molecule PAD4 inhibitors, with the goal of bringing ...
“We believe that CAR-Tregs are the next frontier of cell therapy and represent a potentially transformational approach to solid organ transplantation as well as to many challenging autoimmune and inflammatory conditions. The STEADFAST Phase 1/2 study is an important milestone for genomic medicine that we anticipate will yield insights regarding CAR-Treg ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs. ...
Founded in 2007, SetPoint is dedicated to developing technologies to treat patients with chronic autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s disease and other chronic autoimmune ...
Oral presentation, Program Number S29.004, Session S29: Autoimmune Neurology: Clinical Trials, Treatment, and Diagnosis of CNS and PNS Autoimmune Neurologic Disorders, April 21, 2021, 4:00 p.m. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that the American Institute for Biological and Medical Engineering (AIMBE) has elected Murthy Simhambhatla, PhD, to the AIMBE College of Fellows for “outstanding contributions as a medical technology innovator and business leader, advancing ...
Study results are expected towards the end of 2021 and will provide the basis for future clinical trials both in systemic sclerosis and potentially other chronic inflammatory diseases. Systemic sclerosis is a progressive, autoimmune disease that leads to serious damage to the microvasculature. ...
During his 20 years in the pharmaceutical and biotech industry, he has led numerous drug development programs from discovery through early clinical stage, with a focus on therapies for cancer, chronic viral, autoimmune and inflammatory diseases, including overseeing development of the immunomodulatory anti-PD-1 monoclonal antibody Keytruda, and chairing the ...
It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. ...
The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option. ...
” “These new data confirm that activation of the cholinergic anti-inflammatory pathway by vagus nerve stimulation can reduce disease activity even in patients who have failed to respond to multiple classes of biological drugs and JAK inhibitors,” said Dr. ...
” “These new data confirm that activation of the cholinergic anti-inflammatory pathway by vagus nerve stimulation can reduce disease activity even in patients who have failed to respond to multiple classes of biological drugs and JAK inhibitors,” said Dr. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. ...
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. ...
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. ...